Comparative Pharmacology
Head-to-head clinical analysis: NEO FRADIN versus XERAVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEO FRADIN versus XERAVA.
NEO-FRADIN vs XERAVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis. It also disrupts bacterial cell membrane integrity.
Eravacycline is a tetracycline-class antibacterial that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A-site. It exhibits activity against a broad range of Gram-positive, Gram-negative, and anaerobic bacteria, including many tetracycline-resistant strains due to modifications circumventing common resistance mechanisms.
50-100 mg/kg/day orally in 3-4 divided doses. Maximum 3 g/day.
200 mg intravenously over 60 minutes every 12 hours
None Documented
None Documented
2-3 hours in normal renal function; prolonged to 24-30 hours in anuria or severe renal impairment; no significant change in hepatic disease.
Terminal elimination half-life is approximately 42 hours (range 30-60 hours) in healthy subjects; prolonged in elderly patients and those with severe hepatic impairment.
Renal: >90% unchanged drug via glomerular filtration, with small amount reabsorbed; biliary/fecal: <2%.
Fecal (approximately 80-90% as unchanged drug); renal (less than 1% as unchanged drug).
Category C
Category C
Antibiotic
Antibiotic